NCT02507583 2025-05-07
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
Thomas Jefferson University
Phase 1 Completed
Clinical Trials
13 trialsNCT02794883 2022-04-18
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Northwestern University
Phase 2 Completed
NCT01644955 2018-07-02
Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01213407 2016-05-19
GBM-Vax
Activartis Biotech
Phase 2 Completed
NCT00003484 2015-04-23
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Duke University
Phase 1 Completed
NCT00024570 2014-11-14
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Completed
NCT00003461 2014-08-21
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
Duke University
Phase 1/2 Completed
NCT00003876 2013-06-26
Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003467 2013-06-20
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
Duke University
Phase 2 Completed
NCT00089427 2011-07-04
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
INSYS Therapeutics Inc
Phase 1 Completed
NCT00024557 2011-06-06
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
INSYS Therapeutics Inc
Phase 1 Completed
NCT00041587 2011-06-06
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Completed
NCT00076986 2011-06-06
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
INSYS Therapeutics Inc
Phase 3 Completed